Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. (PetMeds) (NASDAQ: PETS) generates a steady flow of corporate, financial, and operational news that is relevant to investors, analysts, and pet healthcare observers. As a national online pet pharmacy and parent company of PetCareRx, PetMeds regularly issues press releases and SEC reports covering its business performance, governance, regulatory status, and strategic developments.
News about PetMed Express often includes updates on its financial reporting, such as the filing of its Annual Report on Form 10-K and preliminary revenue information for fiscal quarters. The company has reported on investigations by its Audit Committee into accounting and control matters, the resulting restatement of certain prior financial statements, and the identification of material weaknesses in internal control over financial reporting. Related news items also cover notices from Nasdaq regarding delayed SEC filings and the company’s plans to regain compliance with listing requirements.
Corporate governance and leadership changes are another frequent news theme. PetMed Express has announced the resignation of senior executives, the appointment of an interim Chief Executive Officer and an interim principal financial officer, and the addition of independent directors with audit and financial expertise to its board. These updates provide insight into how the company is addressing oversight, financial governance, and board composition.
Strategic and transactional news includes unsolicited, non-binding acquisition proposals from investment firms such as SilverCape Investments Limited and Cardone Ventures, each expressing interest in acquiring all outstanding shares of PetMed Express at a specified cash price per share, subject to customary conditions. The company has also highlighted partnerships and initiatives in the pet healthcare community, such as fundraising efforts with the myBalto Foundation to support emergency veterinary care. Together, these news items offer a detailed view of PetMed Express’s evolving business, governance, and strategic landscape.
PetMed Express (NASDAQ: PETS) has received a notification from Nasdaq on July 2, 2025, regarding non-compliance with listing rules due to delayed filing of its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
The company has until September 1, 2025 to submit a compliance plan to Nasdaq, which may grant an extension until December 29, 2025 to regain compliance. PetMeds previously filed a Form 12b-25 on June 16, 2025, citing the need for additional time to compile and analyze financial information. The notice has no immediate impact on the company's Nasdaq listing status.
PetMed Express (NASDAQ: PETS), operating as PetMeds and parent company of PetCareRx, announced it will be unable to file its Form 10-K for FY 2025 within the extension period ending July 1, 2025. The delay is due to an ongoing investigation initiated by the Audit Committee following anonymous whistleblower reports.
The whistleblower complaints concern three main issues: revenue recognition timing for certain autoship orders in Q4 2025 that led to customer complaints, a $50 coupon promotion's impact on new customer KPIs, and concerns about the company's culture and control environment. The Audit Committee has engaged external legal counsel and advisors to investigate these matters.
Despite the ongoing investigation, PetMed Express states that based on current evidence, they do not expect the investigation to materially impact their previously announced preliminary Q4 and FY 2025 financial results or previously filed financial statements.
[ "Company does not expect material impact on previously announced financial results", "External legal counsel and advisors engaged for thorough investigation", "Company has established whistleblower reporting system in place" ]PetMed Express (NASDAQ: PETS) has announced a strategic partnership with Wagmo, a pet healthcare benefits provider. Through this collaboration, Wagmo members will receive exclusive benefits, including a $25 credit for new PetMeds accounts.
The partnership enhances Wagmo's Perks Program by providing members with access to discounted pet health products, including medications, supplements, nutritional foods, and daily care essentials for dogs and cats. This initiative aims to make comprehensive pet healthcare more accessible and affordable for employees through workplace benefits.
PetMed Express (NASDAQ: PETS), the parent company of PetCareRx, has scheduled its fourth quarter and full fiscal year 2025 earnings conference call for Tuesday, June 10, 2025, at 4:30 PM Eastern Time. The company will release its financial results for the period ended March 31, 2025, before the call.
The management team will host the call followed by a Q&A session. Investors can join via U.S. dial-in (877-407-0789) or international number (201-689-8562). A replay will be available until June 24, 2025, accessible through toll-free (844-512-2921) or international (412-317-6671) numbers using passcode 13753433.
PetMed Express (NASDAQ: PETS) has announced a strategic partnership with Dutch, a virtual veterinary care provider, to expand accessible telehealth services for pets. Through this collaboration, pet parents can access Dutch's virtual veterinary team for 24/7 appointments in 34 states via a monthly membership program. Dutch's platform has completed nearly 700,000 visits and offers treatment for over 150 conditions.
The partnership aims to address the nationwide veterinarian shortage affecting 129 million Americans (38% of the population) who live in vet-care "deserts." Dutch's virtual care platform will integrate with PetMeds' medication services, enabling pet parents to obtain prescriptions efficiently while ensuring professional veterinary guidance remains central to pet healthcare.
PetMed Express (NASDAQ: PETS) is set to ring the Nasdaq Opening Bell on April 11, 2025, in celebration of National Pet Day. The ceremony will feature adoptable rescue dogs from Bidawee, one of the nation's oldest no-kill animal welfare organizations.
Sandra Campos, President & CEO of PetMeds and PetCareRx®, who personally owns three rescue dogs, nine rescue horses, and a senior cat, emphasized the company's commitment to accessible, preventative pet healthcare. The event highlights PetMeds' support for rescue efforts nationwide through their integrated platform, which provides:
- Prescription medications
- Vet-recommended food and supplies
- Trusted guidance and science-backed solutions
Pet lovers are encouraged to participate by sharing their rescue stories on social media using #PawsontheBell and tagging @PetMeds.
PetMed Express (NASDAQ: PETS) has appointed Peter Batushansky to its Board of Directors, effective April 09, 2025. Batushansky, currently a Partner at L2 Capital Partners, brings over 20 years of experience in retail, pet, healthcare, and private equity sectors, including executive roles at WebEyeCare and Allivet.
The appointment marks the third independent director addition since 2024, bringing the board to seven members, with six being independent. Dr. Gian Fulgoni, longtime board member and former Chairman, will retire at the 2025 annual shareholders' meeting.
This appointment follows recent leadership changes, including Leslie C. G. Campbell as Board Chairman in Q4 2024, Sandra Campos as CEO and President in Q1 2025, and new executives in CFO, CAO, COO, and Chief Digital roles. Justin Mennen and Leah Solivan joined the Board in Q2 2025.
PetMed Express (NASDAQ: PETS) has reported its Q3 fiscal 2025 financial results, highlighting several key improvements in its business performance. The company achieved net sales of $53.0 million and improved its gross margin rate to 28.1%, representing an 80 basis points increase compared to the previous year.
The company's Adjusted EBITDA reached $2.0 million, showing a significant improvement from $0.9 million in the prior year period. Management successfully reduced G&A expenses by $2.6 million compared to last year, demonstrating progress in their transformation initiatives focused on operational excellence and financial discipline.
FAQ
What is the current stock price of Petmed Express (PETS)?
What is the market cap of Petmed Express (PETS)?
